The first ever assessment and comparison of pancreatic cancer care in Europe – the European Pancreatic Cancer Index (EPCI) – will be published on March 18, 2014. The EPCI has been developed by the Health Consumer Powerhouse (HCP), with the assistance of an unrestricted grant from Celgene.
Pancreatic cancer is known as a “silent killer”, despite being the third largest cause of death from cancers in the EU. The HCP hope that the launch of the Euro Pancreatic Cancer Index in March 2014 will provide the attention the disease urgently requires. To date, there has been little analysis of the type and quality of medical care given to patients with pancreatic cancer across Europe. The EPCI will change this, by publishing the first systematic assessment and comparison of pancreatic cancer care in Europe – the European Pancreatic Cancer Index (EPCI).
Dr. Anne-Marie Yazbeck, the EPCI project leader at HCP, expects the outcomes to act as a wake-up call for Europe’s health policymakers, saying “We have not yet fully completed the analysis of all the outcomes among the 30 countries covered by the EPCI. However we have already found a worrying lack of information about many of the essential components of care for pancreatic cancer patients”.
“What is emerging from this work is that even healthcare systems and the medical profession have gaps in their knowledge about this form of cancer. This poses the key question: How do such knowledge gaps affect treatment and chances of survival?”
The results of the index will be launched on March 18th, in a webinar 10:00 hrs. A pre-launch webinar providing background information about pancreatic cancer and information deficit will be held on February 24th 10:00 hrs. You are welcome to attend both the webinars, which are free of charge, and the content can be downloaded. To watch the webinars, just enter healthpowerhouse.com.
We will post regular updates on this page, on Twitter @HCPhealthindex and at our Facebook page
You can contact us at firstname.lastname@example.org.